Tharimmune Employees

As of December 31, 2023, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

50.00%

Revenue / Employee

n/a

Profits / Employee

-$4,065,856

Market Cap

3.14M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

THAR News

5 hours ago - Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Accesswire
7 days ago - Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Accesswire
27 days ago - Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Accesswire
2 months ago - Tharimmune to Present at the Microcap Conference 2025 - Accesswire
3 months ago - Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Accesswire
4 months ago - Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Accesswire
4 months ago - Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Accesswire
4 months ago - Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics - Accesswire

More News